Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill for coronary microvascular dysfunction
ChiCTR2000034817Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Coronary Small Vessel Disease (CMD) comparing Shexiang Baoxin Pill arm with Placebo arm (2 arms). Primary endpoint: Abnormal heart rate recovery rate (HRR) during exercise treadmill ECG test at end of treatment. Started Jun 2020; status: recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2000034817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034817.